Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Increased circulating IL-2Rα (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: a comprehensive cytokine–phenotype study

Leukemia volume 27, pages 1430–1433 (2013)Cite this article

Subjects

The clinical phenotype of systemic mastocytosis (SM) is highly variable; establishing prognosis in individual patients is not trivial. The classification of adult SM patients per the 2008 World Health Organization (WHO) system1 has been validated for its prognostic utility.2 In addition to WHO SM subtype, an independent association between inferior survival and advanced age, weight loss, anemia, thrombocytopenia, hypoalbuminemia and excess bone marrow (BM) blasts has been demonstrated.2 Aside from advanced age, however, the aforementioned parameters are typically applicable only to patients with advanced SM subtypes (that is aggressive SM (ASM), SM associated with clonal non-mast cell lineage disease (SM-AHNMD) or mast cell leukemia). In contrast, patients with indolent SM (ISM) have a normal life expectancy; their risk of transformation to acute leukemia or ASM has been estimated to be 1% and 3%, respectively.3, 4 Predictors of disease progression include advanced age, increased serum β2-microglobulin level and multilineage presence of KITD816V.3

Recent studies in primary myelofibrosis,5 myelodysplastic syndrome6 and diffuse large B-cell lymphoma7 have demonstrated an abnormal circulating cytokine milieu reflecting the host response to clonal proliferation. In these studies, specific cytokines were found to be prognostically relevant, independent of known disease-specific prognostic factors. Here, we conducted a comprehensive analysis of circulating cytokines/chemokines with clinicopathologic and clinical outcome correlations in a cohort of SM patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Horny HP, Metcalfe DD, Bennett JM, Bain BJ, Akin C, Escribano L et al. Mastocytosis. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al (eds) WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues 4th edn. International Agency for Research and Cancer (IARC): Lyon, 2008; pp 54–63.

    Google Scholar 

  2. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009; 113: 5727–5736.

    Article  CAS  PubMed  Google Scholar 

  3. Escribano L, Alvarez-Twose I, Sanchez-Munoz L, Garcia-Montero A, Nunez R, Almeida J et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009; 124: 514–521.

    Article  PubMed  Google Scholar 

  4. Pardanani A, Lim KH, Lasho TL, Finke CM, McClure RF, Li CY et al. WHO subvariants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood 2010; 115: 150–151.

    Article  CAS  PubMed  Google Scholar 

  5. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A . Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 2011; 29: 1356–1363.

    Article  CAS  PubMed  Google Scholar 

  6. Pardanani A, Finke C, Lasho TL, Al-Kali A, Begna KH, Hanson CA et al. IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromes. Leukemia 2012; 26: 693–699.

    Article  CAS  PubMed  Google Scholar 

  7. Ansell SM, Maurer MJ, Ziesmer SC, Slager SL, Habermann TM, Link BK et al. Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. Am J Hematol 2012; 87: 865–869.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.

    Article  CAS  PubMed  Google Scholar 

  9. Akin C, Schwartz LB, Kitoh T, Obayashi H, Worobec AS, Scott LM et al. Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology. Blood 2000; 96: 1267–1273.

    CAS  PubMed  Google Scholar 

  10. Morgado JM, Sanchez-Munoz L, Teodosio CG, Jara-Acevedo M, Alvarez-Twose I, Matito A et al. Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion. Mod Pathol 2012; 25: 516–521.

    Article  CAS  PubMed  Google Scholar 

  11. Olejniczak K, Kasprzak A . Biological properties of interleukin 2 and its role in pathogenesis of selected diseases—a review. Med Sci Monit 2008; 14: RA179–RA189.

    CAS  PubMed  Google Scholar 

  12. Horny HP, Sotlar K, Sperr WR, Valent P . Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 2004; 57: 604–608.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Yang ZZ, Grote DM, Ziesmer SC, Manske MK, Witzig TE, Novak AJ et al. Soluble IL-2Ralpha facilitates IL-2-mediated immune responses and predicts reduced survival in follicular B-cell non-Hodgkin lymphoma. Blood 2011; 118: 2809–2820.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, Alvarez-Twose I, Sanchez-Munoz L, Almeida J et al. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis. Leukemia 2012; 26: 951–958.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The current project was partly funded by a grant from the Predolin Foundation for Leukemia Research.

Author Contributions

AP and AT contributed patients, analyzed the data and wrote the initial draft of the manuscript. RAA abstracted clinical data from the medical record. CF and TLL performed the plasma cytokine profiling. CAH provided hematopathology review. All authors approved the final version of the paper for submission.

Author information

Authors and Affiliations

  1. Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA

    A Pardanani, C Finke, R A Abdelrahman, T L Lasho & A Tefferi

  2. Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

    C A Hanson

Authors
  1. A Pardanani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Finke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R A Abdelrahman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T L Lasho
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C A Hanson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Tefferi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A Pardanani.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pardanani, A., Finke, C., Abdelrahman, R. et al. Increased circulating IL-2Rα (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: a comprehensive cytokine–phenotype study. Leukemia 27, 1430–1433 (2013). https://doi.org/10.1038/leu.2013.11

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2013.11

This article is cited by

Search

Advanced search

Quick links